Drug discovery from the age of information to the age of intelligence

Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.

Spotlight

Bioforce Solutions

Bioforce Solutions is a consulting services and staff augmentation firm focused on serving Biotechnology Companies, Pharmaceutical Companies and Medical Device Companies.

OTHER ARTICLES
MedTech

AI and Biotechnology: The Future of Healthcare Industry

Article | July 16, 2022

Artificial intelligence has grasped the foundation in biotech. It can have the most innovative impact on biotechnology. AI has already established its presence in our day-to-day life. AI has made the existence of self-driving cars possible. Likewise, the benefits and quality that it can contribute to biotech can also be felt. With AI, bio technicians will be able to enhance virtual screening, overlook preliminary datasets from clinics, and decipher an enormous amount of information. It can also help in improving the medication process by gathering and analyzing every bit of information. The Significance of AI in Biotechnology In the past few years, the application of artificial intelligence in the biotechnology industry has shifted from being sci-fi to sci-fact. A vast number of biotech companies like Deep Genomics are adopting AI for making data-driven decisions and use analytics tools to work efficiently. Unlike the AI robots in sci-fi that are ready to take over the world. AI designed for biotech has been designed to solve certain problems or complete a bunch of tasks by using automated algorithms. The aim of AI technology for biotech is to collect insights along with hidden patterns from large amounts of data. All the different industries of biotech including agriculture, animal, medical, industrial, and bioinformatics are gradually being affected by artificial intelligence. Moreover, the biotech industry is realizing that AI enables them some of the important strength to their business, including: Expanding accessibility Cost-effectiveness Critical predictions Efficient decision-making Research centers like PwC have also estimated output of $15.7 trillion by 2030 solely with AI contribution in industries. A survey revealed that about 44% of life science experts are using AI for R&D activities, as well. Use of AI in Biotechnology Altering Biomedical and Clinical Data So far the most developed use of AI is its ability to read voluminous data records and interpret them. It can prove to be a life-save for bio technicians who would have to examine that much data from research publications by themselves for the validation of their hypothesis. With the help of AI, clinical studies of patients will also become easier as all the examination reports and prescriptions will be stored in one place for cross-reference. Furthermore, it will also help in blending and fetching data into usable formats for analysis. Test Result Prediction Through trial and error, AI along with machine learning can help in predicting the response of the patient to certain drugs to provide more effective outcomes. Drug Design & Discovery AI plays a vital role whether it’s designing a new molecule or identifying new biological targets. It helps in identifying and validating drugs. It reduces the cost and time spent on the entire drug trial process and reaches the market. Personalized Medications for Rare Diseases With the combination of body scan results, patients’ body and analytics, AI can also help in detecting dangerous diseases at an early stage. Improving Process of Manufacturing To improve the process of manufacturing in biotechnology, AI offers a wide range of opportunities. It controls quality, reduces wastage, improves useability, and minimizes the designing time. Moving Towards AI-Enhanced Biotech Future Ever since the concept of artificial intelligence has arrived, being curious by nature, humans have started working towards achieving this goal. It has been growing at a fast pace while showing unbelievable growth and achievements at times. In comparison to the traditional methods used in the biotechnology industry, AI-based methods seem more reliable and accurate. In the upcoming years, it will show its success by improving the quality of health people have. You can also develop your AI-based application or know more about it by taking IT consultations.

Read More
Medical

Better Purification and Recovery in Bioprocessing

Article | July 14, 2022

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
MedTech

Expansion of BioPharma: Opportunities and Investments

Article | July 12, 2022

Biopharmaceutical innovations are among the most ingenious and refined achievements of modern medical science. New concepts, techniques, and therapies are emerging, such as the cell therapy Provenge, which can be used to treat cancer, and gene therapies, which provide even more amazing promises of disease remission and regenerative medicine. In addition, the COVID-19 pandemic has caused a huge boom in the pharmaceutical industry. This is because more and more attention is being paid to increasing manufacturing capacity and starting new research on drug development. Biopharma: Leading the Way in the Pharma Sector In the past couple of years, the biopharmaceutical sector has deepened its roots across the medical and pharmaceutical industries, on account of the transformation of pharmaceutical companies towards biotechnology, creating opportunities for growth. Also, growing advancements in technologies such as 3D bioprinting, biosensors, and gene editing, along with the integration of advanced artificial intelligence and virtual and augmented reality are estimated to further create prospects for growth. According to a study, the biopharmaceutical sector makes nearly $163 billion around the world and grows by more than 8% each year, which is twice as fast as the traditional pharma sector. Massive Investments Directed Towards Biopharma Investing in biotech research and development (R&D) has yielded better returns than the pharma industry average. Hence, a number of pharmaceutical companies are shifting their presence toward biopharma to capitalize on the upcoming opportunities by investing in and expanding their biotechnology infrastructure. For instance, Thermo Fisher Scientific Inc., an American manufacturer of scientific instrumentation, reagents and consumables, and software services, announced an investment of $97 million to expand its bioanalytical laboratory operations into three new locations in the U.S. With this investment, the company will add 150,000 square feet of scientific workspace and install the most advanced drug development technologies to produce life-changing medicines for patients in need.

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Spotlight

Bioforce Solutions

Bioforce Solutions is a consulting services and staff augmentation firm focused on serving Biotechnology Companies, Pharmaceutical Companies and Medical Device Companies.

Related News

Medical

NiKang Therapeutics Completes $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital. All existing investors, including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital, participated in the financing. About the funding, Bing Yao, Ph.D., former CEO and chairman of Viela Bio, and Ting Jia, Ph.D., founder and chief investment officer of Octagon Capital Advisors, will join NiKang’s Board of Directors. “We are thrilled to have such an outstanding group of investors as our shareholders,” said Zhenhai Gao, Ph.D., co-founder, president, and chief executive officer of NiKang. “Their support of our vision allows us to build the world’s leading precision oncology company. We are now well-positioned to rapidly advance our pipeline into the clinic, including our differentiated HIF-2 alpha inhibitor, and to bring our company to the next level of growth.” “This financing is a testament to the quality of our science and team,” Kelsey Chen, Ph.D., MBA, chief financial officer, added. “Since joining NiKang, I have witnessed the passion and dedication of a group of talented scientists who are devoting their lives to advancing treatments for patients. We are grateful to be recognized by such a high-caliber group of investors.” “NiKang has made remarkable progress over the last eight months since our initial investment,” said Ting Jia, Ph.D., a chief investment officer of Octagon. “We are impressed by the team’s accomplishment. We believe NiKang’s unique approach to attacking difficult-to-drug targets offers promising opportunities to develop breakthrough treatments for cancer patients. We are excited to co-lead the series C financing and partner with the NiKang team to accelerate its growth.” “We are proud of what NiKang has achieved since its inception,” said Sean Cao, executive chairman of NiKang and managing director of CBC Group, which incubated the company. “The strength of this group of investors validates NiKang’s achievements and demonstrates their confidence in NiKang’s potential to grow into a leading innovative drug company.” Proceeds will be used to advance the company’s lead drug candidates into the clinic, expand the pipeline, and fund internal drug discovery programs. About NiKang Therapeutics NiKang Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to assist patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in need.

Read More

Medical

TeselaGen Biotechnology Announced the Launch of a New Protein Optimization Toolkit for Automated Biotherapeutic Drug Design and Development

TeselaGen Biotechnology | May 21, 2021

TeselaGen Biotechnology today announced the launch of a new protein optimization toolkit for biotherapeutic drug design and development, introducing significant enhancements to the company’s flagship TeselaGen® OS to form designing and developing pharmaceuticals and biotherapeutics faster and fewer expensive. The new capabilities, easily accessible via the cloud-based platform, simplify the planning of highly complex combinatorial protein libraries and support AI models for optimizing new peptides and proteins. New application programming interfaces (APIs) and integration tools have also been extended to further enhance users’ access to the new capabilities. TeselaGen integrates the facility of AI with one end-to-end platform for design, construction, data gathering, and analysis of bioproduct performance, from pharmaceuticals to food and fabrics, significantly accelerating time to plug and reducing costs. The platform’s DESIGN, BUILD, TEST, and find out modules enable researchers to effectively collaborate across an organization's development pipeline to style and build experiments, standardize and share data, and learn and preserve project results by embedding them during a machine learning model. TeselaGen’s DESIGN is an intuitive, user-interface-driven module that permits scientists to style highly complex combinatorial libraries. With this new release, the planning now supports aminoalkanoic acid parts which will be efficiently mapped to DNA. TeselaGen can then automatically generate biology protocols for efficiently synthesizing and assembling the corresponding DNA libraries. TeselaGen’s DISCOVER now supports AI models which will recommend new peptides and proteins supported by the training of supervised and unsupervised learning models. The platform also supports the modeling of unnatural amino acids and multicriteria optimization of proteins. R&D groups can utilize the TeselaGen OS to hurry the invention process. Datasets are uploaded and arranged within the platform and immediately useful for model building within TeselaGen’s DISCOVER module. TeselaGen has demonstrated that it can increase the planning and build speed of biological products and reduce the prices related to research & development by an order of magnitude. Current partnering companies are using the new capabilities for designing antibodies and optimizing their binding affinity, titer, specific productivity, immunogenicity, or other phenotypic variables of interest. Researchers also are looking to TeselaGen for rapidly engineering new vaccines - using methods like virus-like particles (VLPs), DNA, and RNA vaccines - opening the door to attacking rapidly mutating RNA and retroviruses like influenza, HCV, HIV, or coronaviruses. About TeselaGen Biotechnology TeselaGen Biotechnology has developed the primary artificial intelligence-enabled OS for biotechnology, enabling the event and commercialization of high-performance bioproducts – from pharmaceuticals to food to fabrics – faster and easier than ever. TeselaGen® connects biologists, lab technicians, and bioinformaticians so that they will collaboratively design and build experiments, organize and standardize data then test and continually learn from the info. TeselaGen has been deployed by Fortune 50 companies and emerging innovators in biopharmaceuticals, agriculture, and specialty chemicals. the corporate is privately held and based in San Francisco, California.

Read More

AI

Iktos Partners with Kadmon to Use AI for New Drug Design

Iktos, Kadmon | May 19, 2021

Iktos, a company specializing in Artificial Intelligence for new drug design, announced today that it has signed a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, under which Iktos' generative modeling artificial intelligence (AI) technology will be used to allow the rapid and cost-effective design of novel drug candidates. Iktos will use its de novo structure-based generative modeling technologies to find novel compounds that meet a pre-defined target product profile as part of the deal, to speed up Kadmon's early-stage discovery efforts. Kadmon discovers, develops, and delivers small molecules and biologics for the treatment of human diseases. Intending to identify and develop new product candidates for significant unmet medical needs, Kadmon is expanding and incorporating novel drug discovery platforms. The AI technology developed by Iktos, which is focused on deep generative models, aids in the speed and efficiency of the drug discovery process. Iktos' technology creates virtual novel molecules that have all of the properties of a successful drug molecule automatically. This approach, which has been validated by Iktos' other collaborations, is an innovative approach to one of the most difficult problems in drug design: finding molecules that meet several important drug criteria at the same time, such as potency, selectivity, safety, and project-specific properties. Iktos' technology enables the creation of new hits with optimal protein-ligand interactions in early-stage discovery projects, as predicted by molecular modeling technology. This technique allows for a one-of-a-kind discovery of chemical space, as well as the development of innovative molecule designs with greater Freedom to Operate. Furthermore, allowing multi-parametric in silico optimization from the start of a project greatly reduces the hit finding and hit-to-lead optimization phases. About Iktos Iktos, a French start-up founded in October 2016, specializes in the development of artificial intelligence technologies for chemical research, especially medicinal chemistry, and new drug design. Iktos is working on a proprietary and innovative approach focused on deep learning generative models that allow users to build molecules in silico that follow all of the performance criteria of a small molecule discovery project using existing evidence. Iktos technology allows for significant efficiency gains in upstream pharmaceutical R&D. Iktos' software is utilized as both professional services and a SaaS software platform, Makya. Spaya, a synthesis planning software built on Iktos' proprietary AI technology for retrosynthesis, is also in the works.

Read More

Medical

NiKang Therapeutics Completes $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital. All existing investors, including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital, participated in the financing. About the funding, Bing Yao, Ph.D., former CEO and chairman of Viela Bio, and Ting Jia, Ph.D., founder and chief investment officer of Octagon Capital Advisors, will join NiKang’s Board of Directors. “We are thrilled to have such an outstanding group of investors as our shareholders,” said Zhenhai Gao, Ph.D., co-founder, president, and chief executive officer of NiKang. “Their support of our vision allows us to build the world’s leading precision oncology company. We are now well-positioned to rapidly advance our pipeline into the clinic, including our differentiated HIF-2 alpha inhibitor, and to bring our company to the next level of growth.” “This financing is a testament to the quality of our science and team,” Kelsey Chen, Ph.D., MBA, chief financial officer, added. “Since joining NiKang, I have witnessed the passion and dedication of a group of talented scientists who are devoting their lives to advancing treatments for patients. We are grateful to be recognized by such a high-caliber group of investors.” “NiKang has made remarkable progress over the last eight months since our initial investment,” said Ting Jia, Ph.D., a chief investment officer of Octagon. “We are impressed by the team’s accomplishment. We believe NiKang’s unique approach to attacking difficult-to-drug targets offers promising opportunities to develop breakthrough treatments for cancer patients. We are excited to co-lead the series C financing and partner with the NiKang team to accelerate its growth.” “We are proud of what NiKang has achieved since its inception,” said Sean Cao, executive chairman of NiKang and managing director of CBC Group, which incubated the company. “The strength of this group of investors validates NiKang’s achievements and demonstrates their confidence in NiKang’s potential to grow into a leading innovative drug company.” Proceeds will be used to advance the company’s lead drug candidates into the clinic, expand the pipeline, and fund internal drug discovery programs. About NiKang Therapeutics NiKang Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to assist patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in need.

Read More

Medical

TeselaGen Biotechnology Announced the Launch of a New Protein Optimization Toolkit for Automated Biotherapeutic Drug Design and Development

TeselaGen Biotechnology | May 21, 2021

TeselaGen Biotechnology today announced the launch of a new protein optimization toolkit for biotherapeutic drug design and development, introducing significant enhancements to the company’s flagship TeselaGen® OS to form designing and developing pharmaceuticals and biotherapeutics faster and fewer expensive. The new capabilities, easily accessible via the cloud-based platform, simplify the planning of highly complex combinatorial protein libraries and support AI models for optimizing new peptides and proteins. New application programming interfaces (APIs) and integration tools have also been extended to further enhance users’ access to the new capabilities. TeselaGen integrates the facility of AI with one end-to-end platform for design, construction, data gathering, and analysis of bioproduct performance, from pharmaceuticals to food and fabrics, significantly accelerating time to plug and reducing costs. The platform’s DESIGN, BUILD, TEST, and find out modules enable researchers to effectively collaborate across an organization's development pipeline to style and build experiments, standardize and share data, and learn and preserve project results by embedding them during a machine learning model. TeselaGen’s DESIGN is an intuitive, user-interface-driven module that permits scientists to style highly complex combinatorial libraries. With this new release, the planning now supports aminoalkanoic acid parts which will be efficiently mapped to DNA. TeselaGen can then automatically generate biology protocols for efficiently synthesizing and assembling the corresponding DNA libraries. TeselaGen’s DISCOVER now supports AI models which will recommend new peptides and proteins supported by the training of supervised and unsupervised learning models. The platform also supports the modeling of unnatural amino acids and multicriteria optimization of proteins. R&D groups can utilize the TeselaGen OS to hurry the invention process. Datasets are uploaded and arranged within the platform and immediately useful for model building within TeselaGen’s DISCOVER module. TeselaGen has demonstrated that it can increase the planning and build speed of biological products and reduce the prices related to research & development by an order of magnitude. Current partnering companies are using the new capabilities for designing antibodies and optimizing their binding affinity, titer, specific productivity, immunogenicity, or other phenotypic variables of interest. Researchers also are looking to TeselaGen for rapidly engineering new vaccines - using methods like virus-like particles (VLPs), DNA, and RNA vaccines - opening the door to attacking rapidly mutating RNA and retroviruses like influenza, HCV, HIV, or coronaviruses. About TeselaGen Biotechnology TeselaGen Biotechnology has developed the primary artificial intelligence-enabled OS for biotechnology, enabling the event and commercialization of high-performance bioproducts – from pharmaceuticals to food to fabrics – faster and easier than ever. TeselaGen® connects biologists, lab technicians, and bioinformaticians so that they will collaboratively design and build experiments, organize and standardize data then test and continually learn from the info. TeselaGen has been deployed by Fortune 50 companies and emerging innovators in biopharmaceuticals, agriculture, and specialty chemicals. the corporate is privately held and based in San Francisco, California.

Read More

AI

Iktos Partners with Kadmon to Use AI for New Drug Design

Iktos, Kadmon | May 19, 2021

Iktos, a company specializing in Artificial Intelligence for new drug design, announced today that it has signed a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, under which Iktos' generative modeling artificial intelligence (AI) technology will be used to allow the rapid and cost-effective design of novel drug candidates. Iktos will use its de novo structure-based generative modeling technologies to find novel compounds that meet a pre-defined target product profile as part of the deal, to speed up Kadmon's early-stage discovery efforts. Kadmon discovers, develops, and delivers small molecules and biologics for the treatment of human diseases. Intending to identify and develop new product candidates for significant unmet medical needs, Kadmon is expanding and incorporating novel drug discovery platforms. The AI technology developed by Iktos, which is focused on deep generative models, aids in the speed and efficiency of the drug discovery process. Iktos' technology creates virtual novel molecules that have all of the properties of a successful drug molecule automatically. This approach, which has been validated by Iktos' other collaborations, is an innovative approach to one of the most difficult problems in drug design: finding molecules that meet several important drug criteria at the same time, such as potency, selectivity, safety, and project-specific properties. Iktos' technology enables the creation of new hits with optimal protein-ligand interactions in early-stage discovery projects, as predicted by molecular modeling technology. This technique allows for a one-of-a-kind discovery of chemical space, as well as the development of innovative molecule designs with greater Freedom to Operate. Furthermore, allowing multi-parametric in silico optimization from the start of a project greatly reduces the hit finding and hit-to-lead optimization phases. About Iktos Iktos, a French start-up founded in October 2016, specializes in the development of artificial intelligence technologies for chemical research, especially medicinal chemistry, and new drug design. Iktos is working on a proprietary and innovative approach focused on deep learning generative models that allow users to build molecules in silico that follow all of the performance criteria of a small molecule discovery project using existing evidence. Iktos technology allows for significant efficiency gains in upstream pharmaceutical R&D. Iktos' software is utilized as both professional services and a SaaS software platform, Makya. Spaya, a synthesis planning software built on Iktos' proprietary AI technology for retrosynthesis, is also in the works.

Read More

Events